美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

301.13

+1.190.40%

盤後：301.190.0600+0.02%16:17 EDT

成交量：50.30萬

成交額：1.51億

市值：357.29億

市盈率：-81.32

高：303.60

開：296.50

低：296.18

收：299.94

資料載入中...

總覽公司新聞公告

國產創新藥破曉時刻！華安醫藥軍團以科技思維定義投資新範式

港股生物醫藥股延續回調，百濟神州跌超8%

老虎资讯综合

6 月，恆瑞、百濟神州、復星醫藥等新藥又有新進展，多個關鍵 III 期臨牀啓動

Insight数据库

解讀全球製藥企業50強榜單：中國創新藥企距離“Big Pharma”還有多遠

每日经济新闻

百濟神州在研發日展示開創性腫瘤治療管線

醫藥估值重估邏輯

资本市场那些事儿

百濟神州百悦澤®片劑獲歐洲藥品管理局人用藥品委員會積極意見

百濟神州6月24日成交額為1.20億美元

"長守護悅新生"2025淋巴瘤患者關愛活動舉行

創新藥大牛市繼續，最受益也是中國最強的創新藥龍頭，沒有之一！

价值事务所

港股創新藥ETF漲2.25%，成交額23.73億元

百濟神州：生物科技出海明星 2025年迎來蝶變

西南证券股份有...

百濟神州6月23日成交額為1.16億美元

【醫藥生物】創新藥審評再次加速，創新藥產業鏈主線持續明確——醫藥生物行業跨市場週報（20250622）（王明瑞）

光大证券研究

百濟神州漲逾3% 百赫安於中國正式投入臨牀使用

生物醫藥：體內CAR-T：全球競賽已打響，關注雲頂新耀和石藥集團

百濟神州宣佈百赫安®在中國正式投入臨牀使用

2025全球製藥50強榜單最新出爐！百濟神州首次上榜

MedTrend医趋势

6月20日百濟神州-UAH溢價達79.85%，位居AH股溢價率第52位

百濟神州6月18日成交額為5867.21萬美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":301.13,"timestamp":1753992000000,"preClose":299.94,"halted":0,"volume":503000,"hourTrading":{"tag":"盘后","latestPrice":301.19,"preClose":301.13,"latestTime":"16:17 EDT","volume":125943,"amount":37919651.42826,"timestamp":1753993067951},"delay":0,"floatShares":75541600,"shares":118650120,"eps":-3.70325,"marketStatus":"盤後交易","change":1.19,"latestTime":"07-31 17:54:26 EDT","open":296.5,"high":303.6,"low":296.1801,"amount":151391015.69786,"amplitude":0.024738,"askPrice":304,"askSize":8,"bidPrice":297,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1754006400000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":299.94,"preHourTrading":{"tag":"盘前","latestPrice":301.81,"preClose":299.94,"latestTime":"09:28 EDT","volume":2,"amount":603.62,"timestamp":1753968480053},"postHourTrading":{"tag":"盘后","latestPrice":301.19,"preClose":301.13,"latestTime":"16:17 EDT","volume":125943,"amount":37919651.42826,"timestamp":1753993067951},"volumeRatio":1.211223,"impliedVol":0.4576,"impliedVolPercentile":0.7569},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.211223,"shares":118650120,"dividePrice":0,"high":303.6,"amplitude":0.024738,"preClose":299.94,"low":296.1801,"week52Low":155.75,"pbRate":"10.21","psRate":"8.56","week52High":308.87,"institutionHeld":0,"latestPrice":301.13,"committee":0.851852,"eps":-3.70325,"divideRate":0,"volume":503000,"delay":0,"ttmEps":-3.70325,"open":296.5,"prevYearClose":184.71,"prevWeekClose":291.47,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":296.46,"twentyDayClose":244.32,"sixtyDayClose":254.16,"earningDate":1756483200000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546761985","title":"國產創新藥破曉時刻！華安醫藥軍團以科技思維定義投資新範式","url":"https://stock-news.laohu8.com/highlight/detail?id=2546761985","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546761985?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 10:20","pubTimestamp":1750990844,"startTime":"0","endTime":"0","summary":"华安医药军团凭借多元化产品矩阵满足不同需求，汇聚产业专家，以科技投资思维构建研究体系。创新药的“破晓时刻”，医药投资的复苏拐点 在国内政策强力扶持、全球竞争力显著提升、出海浪潮集中爆发等多重因素驱动下，2025年，中国创新药行业迎来了属于自己的“破晓时刻”。截至一季度末，华安医药生物持仓包括港股市场和A股市场中多只涨幅明显的创新药个股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627102044a71fcded&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627102044a71fcded&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","688235","688428","BK4139","06160","ONC","BK4526"],"gpt_icon":0},{"id":"1106218367","title":"港股生物醫藥股延續回調，百濟神州跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106218367","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106218367?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 10:13","pubTimestamp":1750990427,"startTime":"0","endTime":"0","summary":"6月27日，港股生物医药股延续回调，百济神州跌超8%，荣昌生物跌超7%，北海康成跌超6%，加科思、中国再生医学、药明巨诺跌超4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","399441","BK4526","07226","06160","HSCEI","688235","161726","LU2328871848.SGD","BK4614","LU1969619763.USD","LU0307460666.USD","BK1588","BK1161","BK4139","HSTECH","BK1500","ONC","BK0239","LU0588546209.SGD"],"gpt_icon":0},{"id":"2546575067","title":"6 月，恆瑞、百濟神州、復星醫藥等新藥又有新進展，多個關鍵 III 期臨牀啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2546575067","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546575067?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 07:45","pubTimestamp":1750981540,"startTime":"0","endTime":"0","summary":"III 期临床启动，意味着新药研发已经开始向上市申请发起冲刺。据公开资料，这是该药首次启动 III 期临床。国产方面，三生国健的 SSGJ-611 本次启动 COPD III 期临床。此外，康诺亚/石药集团的司普奇拜单抗已启动 II/III 期，康乃德/先声药业的乐德奇拜单抗正在开展 II 期临床。Insight 数据库显示，在低级别胶质瘤赛道上，国内暂未有相关药物获批上市，芦沃美替尼研发进度位列第一梯队，已开展 III 期关键临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627075121a4bfe6d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627075121a4bfe6d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0183","01276","BK0096","BK0175","BK0196","BK0012","600196","BK0060","BK0028","BK0239","600276","BK0187","688235","02196","06160","ONC"],"gpt_icon":0},{"id":"2546780647","title":"解讀全球製藥企業50強榜單：中國創新藥企距離“Big Pharma”還有多遠","url":"https://stock-news.laohu8.com/highlight/detail?id=2546780647","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546780647?lang=zh_tw&edition=fundamental","pubTime":"2025-06-26 20:02","pubTimestamp":1750939355,"startTime":"0","endTime":"0","summary":"近日，美国《制药经理人》杂志发布2025年全球制药企业50强榜单。从产品潜力和研发趋势来看，中国创新药领域的全球化征程已经起航，成为“Big Pharma”只是时间问题。Evaluate Pharma近期发布的最新预测报告表示，到2030年，GLP-1激动剂及相关复方制剂将占所有处方药销售额的近9%。中国药企在前沿疗法“唱主角”上述榜单显示，今年有6家中国企业上榜，数量创近5年新高，但排名均在30名以后。但中国创新药近年来取得的进步有目共睹。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626200338a4bf27b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626200338a4bf27b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","ONC","688235","06160","BK0239","NVO","MRK"],"gpt_icon":0},{"id":"2546978975","title":"百濟神州在研發日展示開創性腫瘤治療管線","url":"https://stock-news.laohu8.com/highlight/detail?id=2546978975","media":"百济神州","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546978975?lang=zh_tw&edition=fundamental","pubTime":"2025-06-26 18:07","pubTimestamp":1750932471,"startTime":"0","endTime":"0","summary":"在百济神州，我们的使命明确且坚定——致力于成为推动全球新一代肿瘤治疗创新的先行者。如今，百济神州汇集了超过1200名科学家和3700多名临床开发及医学事务的专业人才，共同致力于推动肿瘤治疗领域的持续突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626182027a4beffdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626182027a4beffdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK1500","BK1583","LU0329678337.USD","LU0737861772.HKD","BK1588","06078","LU0329678170.USD","688235","LU0307460666.USD","BK1209","LU2488822045.USD","LU1969619763.USD","BK1161","LU0588546209.SGD","LU2328871848.SGD","ONC"],"gpt_icon":0},{"id":"2546278232","title":"醫藥估值重估邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2546278232","media":"资本市场那些事儿","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546278232?lang=zh_tw&edition=fundamental","pubTime":"2025-06-26 09:14","pubTimestamp":1750900469,"startTime":"0","endTime":"0","summary":"为什么我会提出这个概念，因为2025，有了一些新变化，对比以往的医药行业，估值的重估，开始一步步的被证实了。——海外大佬来“抢货”大药企“囤货式采购”：2025年起，辉瑞、默沙东等国际巨头疯狂抢购中国创新药管线，尤其是早期项目。叠加大药企的专利陆续到期，都到中国来扫货了。2024年32家药企研发投入672亿，35%砸向早期项目。药企猛冲研发，CXO躺赚订单，技术平台型药企和CXO公司都能迎来一波估值重估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626092555a4be36c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626092555a4be36c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK4526","06160","ONC","BK4139","01530","09926"],"gpt_icon":0},{"id":"2546421137","title":"百濟神州百悦澤®片劑獲歐洲藥品管理局人用藥品委員會積極意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2546421137","media":"百济神州","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546421137?lang=zh_tw&edition=fundamental","pubTime":"2025-06-25 18:06","pubTimestamp":1750845997,"startTime":"0","endTime":"0","summary":"美国加州圣卡洛斯——百济神州有限公司是一家全球肿瘤治疗创新公司，今日宣布欧洲药品管理局人用药品委员会发布积极意见，推荐批准百悦泽新的薄膜包衣片剂剂型用于所有已获批适应症。欧盟委员会将对CHMP的积极意见进行审评，如通过批准，片剂剂型在欧盟和欧洲经济区国家挪威和冰岛上市。本新闻稿中的所有信息仅及于新闻稿发布之日，除非法律要求，百济神州并无责任更新该等信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625183749a4bd317c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625183749a4bd317c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK0239","ONC"],"gpt_icon":0},{"id":"2546726445","title":"百濟神州6月24日成交額為1.20億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546726445","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546726445?lang=zh_tw&edition=fundamental","pubTime":"2025-06-25 12:34","pubTimestamp":1750826076,"startTime":"0","endTime":"0","summary":"美东时间2025年6月24日，百济神州成交额为1.20亿美元，成交额较昨日增加3.37%，当日成交量为45.06万股。百济神州于2025年6月24日涨3.61%，报266.8美元，该股过去5个交易日涨0.9%，年初至今涨44.44%，过去60日涨1.6%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625123445a71c564b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625123445a71c564b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2546232068","title":"\"長守護 悅新生\"2025淋巴瘤患者關愛活動舉行","url":"https://stock-news.laohu8.com/highlight/detail?id=2546232068","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546232068?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 21:45","pubTimestamp":1750772700,"startTime":"0","endTime":"0","summary":"\"长守护 悦新生\"2025淋巴瘤患者关爱活动  淋巴瘤是我国最常见的血液系统肿瘤之一，具有分型复杂、起病隐匿、早期诊断难度大、病程长且易复发等特点，为患者及其家庭带来了较为沉重的疾病负担。淋巴瘤患者故事纪录片《英雄》也在活动现场首映。影片讲述了三位不同年龄、不同职业的淋巴瘤患者积极治疗、热爱生活的真实故事，激励更多患友要做生活中的英雄。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4717198_ZH17198_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0307460666.USD","688235","LU0588546209.SGD","BK4139","BK4526","BK1500","ONC","BK1588","LU2328871848.SGD","BK1583","BK1161","06160","BK0239","LU1969619763.USD"],"gpt_icon":0},{"id":"2545805762","title":"創新藥大牛市繼續，最受益也是中國最強的創新藥龍頭，沒有之一！","url":"https://stock-news.laohu8.com/highlight/detail?id=2545805762","media":"价值事务所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545805762?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 20:58","pubTimestamp":1750769912,"startTime":"0","endTime":"0","summary":"连当代创新药的发源地欧美都开始争相关注并报道咱们国内的创新药突破，这其实就已经很能够说明一些问题了。这不仅是百济自身的转折点，其实也是国内创新药行业从 “资本驱动” 迈向 “价值创造” 的重要信号。对大多数 Biotech 而言，这样的路径既是范本，也是九死一生的缩影。创新药的上岸之路，从来都是烧钱换时间的残酷游戏。如今国内创新药崛起之势不","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624210233a4bb8bd9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624210233a4bb8bd9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4614","ONC","06160","YANG","BK4526","688235","BK4139"],"gpt_icon":0},{"id":"2545523545","title":"港股創新藥ETF漲2.25%，成交額23.73億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545523545","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545523545?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 15:04","pubTimestamp":1750748662,"startTime":"0","endTime":"0","summary":"6月24日，港股创新药ETF收盘涨2.25%，成交额23.73亿元。港股创新药ETF成立于2024年1月3日，基金全称为银华国证港股通创新药交易型开放式指数证券投资基金，基金简称为港股创新药ETF。回顾2024年12月31日，港股创新药ETF份额为3.95亿份，规模为3.78亿元。流动性方面，截止6月24日，港股创新药ETF近20个交易日累计成交金额384.34亿元，日均成交金额19.22亿元；今年以来，113个交易日，累计成交金额793.25亿元，日均成交金额7.02亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624222703a4bbaa2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624222703a4bbaa2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2545474477","title":"百濟神州：生物科技出海明星 2025年迎來蝶變","url":"https://stock-news.laohu8.com/highlight/detail?id=2545474477","media":"西南证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545474477?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 13:40","pubTimestamp":1750743628,"startTime":"0","endTime":"0","summary":"2）在研Bcl-2i 和BTK CDAC 于2025 年迎来多项催化事件，未来依托泽布替尼全球商业化渠道，拓宽加深血液瘤市场覆盖。百济神州国内药企出海标杆，预计公司25 年有望盈利。百济神州于2010 年创立，是美股+H 股+A 股三地上市的创新药企业。公司于2025 年JPM 大会宣布当年目标实现营运利润为正。2025 年公司Bcl2i Sonrotoclax 有望完成首个注册临床研究。PanKRASi、EGFR CDAC、CDK2i、多项ADC 有望于2025 年下半年首次读出概念验证数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624134036978c50ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624134036978c50ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","159837","ONC","BK0239","06160"],"gpt_icon":0},{"id":"2545792114","title":"百濟神州6月23日成交額為1.16億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545792114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545792114?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 12:33","pubTimestamp":1750739600,"startTime":"0","endTime":"0","summary":"美东时间2025年6月23日，百济神州成交额为1.16亿美元，成交额较昨日增加103.45%，当日成交量为45.07万股。百济神州于2025年6月23日涨4.22%，报257.51美元，该股过去5个交易日跌4.5%，年初至今涨39.41%，过去60日涨2.63%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624123324a71a8aed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624123324a71a8aed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2545142588","title":"【醫藥生物】創新藥審評再次加速，創新藥產業鏈主線持續明確——醫藥生物行業跨市場週報（20250622）（王明瑞）","url":"https://stock-news.laohu8.com/highlight/detail?id=2545142588","media":"光大证券研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545142588?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 07:02","pubTimestamp":1750719778,"startTime":"0","endTime":"0","summary":"非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。H股恒生医疗健康指数上周收跌7.72%，跑输恒生国企指数6.24pp。众生药业的RAY1225、恒瑞医药的HRS-1893正在进行三期临床；翰森制药的HS-10370、三生制药的SSGJ-612正在进行一期临床。本周观点：创新药审评再次加速，创新药产业链主线持续明确2025年6月16日，国家药监局综合司公开征求《关于优化创新药临床试验审评审批有关事项的公告》意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624070629a71a09c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624070629a71a09c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1593","03692","06160","ONC","BK1583","01530","06978","600276"],"gpt_icon":0},{"id":"2545445611","title":"百濟神州漲逾3% 百赫安 於中國正式投入臨牀使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2545445611","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545445611?lang=zh_tw&edition=fundamental","pubTime":"2025-06-23 22:50","pubTimestamp":1750690206,"startTime":"0","endTime":"0","summary":"周一，百济神州(ONC.US)涨逾3%，报255.81美元。消息面上，百济神州6月23日宣布双特异性HER2抑制剂百赫安(注射用泽尼达妥单抗)在中国正式供应，并同步在全国多家医疗机构投入临床使用。作为中国首个且目前唯一1获批用于靶向治疗HER2高表达胆道癌的双特异性抗体，首批药物将迅速在全国百余个城市的医院和药房落地，惠及胆道癌(BTC)患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623233944a4b96864&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623233944a4b96864&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2545187754","title":"生物醫藥：體內CAR-T：全球競賽已打響，關注雲頂新耀和石藥集團","url":"https://stock-news.laohu8.com/highlight/detail?id=2545187754","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545187754?lang=zh_tw&edition=fundamental","pubTime":"2025-06-23 18:07","pubTimestamp":1750673278,"startTime":"0","endTime":"0","summary":"艾伯维、阿斯利康等多个制药巨头已通过合作/收购布局体内CAR-T赛道。石药集团自主研发的mRNA-LNP的自体CAR-T疗法进入临床，体内CAR-T的布局亦可期待。全球自体CAR-T细胞疗法全球销售额2024年合计超45亿美金，制造过程繁琐、可及性低和价格昂贵的缺点限制其应用。实现体内CAR-T疗法的核心挑战，在于如何将CAR构建体精准、高效且安全地递送至目标T细胞。慢病毒载体可将CAR基因永久整合到宿主T细胞的基因组中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","01801","BK4139","LU2488822045.USD","BK4526","02105","09688","BK4230","BK4022","CAR","BK4585","ZLAB","BK4588","ONC","09926","688235","06160","BK4548","01672","BK4531"],"gpt_icon":0},{"id":"2545413240","title":"百濟神州宣佈百赫安®在中國正式投入臨牀使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2545413240","media":"百济神州","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545413240?lang=zh_tw&edition=fundamental","pubTime":"2025-06-23 18:01","pubTimestamp":1750672903,"startTime":"0","endTime":"0","summary":"中国北京——百济神州有限公司是一家全球肿瘤治疗创新公司，今日宣布双特异性HER2抑制剂百赫安在中国正式供应，并同步在全国多家医疗机构投入临床使用。因此，BTC患者亟需新的临床治疗选择。目前，BTC全球发病率呈现上升趋势，以亚洲国家为常见14。本新闻稿中的所有信息仅及于新闻稿发布之日，除非法律要求，百济神州并无责任更新该等信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623183229a718933b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623183229a718933b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","688235","BK0239"],"gpt_icon":0},{"id":"2545928104","title":"2025全球製藥50強榜單最新出爐！百濟神州首次上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2545928104","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545928104?lang=zh_tw&edition=fundamental","pubTime":"2025-06-21 10:55","pubTimestamp":1750474553,"startTime":"0","endTime":"0","summary":"6月20日晚，美国《制药经理人》杂志重磅“2025 全球制药企业50强”榜单发布，时间对比以往稍晚了一些。其2024年处方药收入增加超过70亿美元，总计509.5亿美元，增幅16.3%。其免疫治疗重磅药Imfinzi在2025年第一季度因需求加速和新适应症获批，销售额增长11.6%。02中国药企全面崛起从中国药企来看，是上榜最多的一次，有6家企业上榜，其中百济神州、华东医药、是新晋上榜，石药集团再次回归。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621105928a715857a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250621105928a715857a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK4139","688235","BK4526"],"gpt_icon":0},{"id":"2544288142","title":"6月20日百濟神州-UAH溢價達79.85%，位居AH股溢價率第52位","url":"https://stock-news.laohu8.com/highlight/detail?id=2544288142","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544288142?lang=zh_tw&edition=fundamental","pubTime":"2025-06-20 16:39","pubTimestamp":1750408774,"startTime":"0","endTime":"0","summary":"6月20日，上证指数跌0.07%，收报3359.9点，恒生指数涨1.26%，收报23530.48点。当日收盘，百济神州-UA股报244.89元，跌幅0.66%，H股报148.8港元，上涨0.74%。资料显示，百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620165757a7142a0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620165757a7142a0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","BK4526","06160"],"gpt_icon":0},{"id":"2544139125","title":"百濟神州6月18日成交額為5867.21萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544139125","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544139125?lang=zh_tw&edition=fundamental","pubTime":"2025-06-19 12:15","pubTimestamp":1750306526,"startTime":"0","endTime":"0","summary":"美东时间2025年6月18日，百济神州成交额为5867.21万美元，成交额较昨日减少45.50%，当日成交量为23.04万股。百济神州于2025年6月18日跌0.52%，报252.78美元，该股过去5个交易日跌3.67%，年初至今涨36.85%，过去60日跌0.17%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619121527a711c1d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619121527a711c1d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":7,"totalSize":164,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null},{"date":"2025-08-06","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.48,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-30","current":-92.454718,"percent":0,"low":-92.454718,"twenty":-49.55219,"median":-39.846451,"eighty":-23.226141,"high":-19.234246,"avg":-41.587495,"sd":19.845611,"marketCap":36276087688},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-07-30","current":-92.454718,"twenty":-49.55219,"median":-39.846451,"eighty":-23.226141,"marketCap":36276087688}],"updateTime":1753998866822}}}